Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum

Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16%

Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global readiness through system upgrades and localization

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results and key operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025.

"Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth." said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "In addition to our strong revenue performance, during the quarter we also made significant progress on the regulatory pathway in seeking U.S. FDA 510(k) clearance and continued scaling our operations globally with system upgrades and localization."

The Company expects to report fiscal fourth quarter 2025 revenue increases of approximately 16% sequentially and year-over-year, reflecting continued demand for its higher-margin cartridge sales and steady account growth. Preliminary results indicate sequential revenue growth over both the fiscal third and second quarters.

Operational Highlights

Submitted FDA 510(k) application for its opiate test system for codeine, supported by new scientific and clinical validation data.

Completed multilingual ...